Compare AbCellera Biologics Inc (ABCL) vs Cloudflare Inc (NET) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

NET trades at $268.77, up 11% today after Scotiabank upgraded the stock citing AI growth potential. The stock shows strong bullish momentum with a consensus analyst rating of 'Buy' (70% of 40 analysts) and a price target of $246.58. Recent earnings beats and revenue growth to $2.17B in 2025 highlight operational strength, though negative net margins and high valuations (P/S 37.22) pose challenges. Technical indicators signal bullish trends with resistance near $262.

Outlook: Growth driven by AI infrastructure demand and strategic partnerships offers upside, but high valuation and lack of profitability increase risk. Investors should weigh robust revenue growth against margin pressures and competitive threats in the cloud sector.